Phase 2 Non-Small-Cell Lung Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 1Phase 2
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled102 locationsNCT06772623
Recruiting
Phase 2
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Squamous Non-small-cell Lung Cancer
Merck Sharp & Dohme LLC180 enrolled51 locationsNCT07221474
Recruiting
Phase 2
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Non-small Cell Lung CancerLung NeoplasmsCarcinoma+6 more
Pfizer120 enrolled3 locationsNCT07489066
Recruiting
Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting
Phase 1Phase 2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+2 more
AstraZeneca460 enrolled67 locationsNCT05123482
Recruiting
Phase 2
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Renal Cell Carcinoma (RCC)Small Cell Lung CancerNon-Small-Cell Lung
Advenchen Pharmaceuticals, LLC.80 enrolled7 locationsNCT05363280
Recruiting
Phase 2
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
Metastatic/Locally Advanced Non-Small-Cell Lung CancerMetastatic/Locally Pancreatic Ductal Adenocarcinoma
Gustave Roussy, Cancer Campus, Grand Paris60 enrolled6 locationsNCT07483983
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 2
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
ToLymph Inc.42 enrolled2 locationsNCT06693336
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSquamous Non-small-cell Lung Cancer+1 more
Alentis Therapeutics AG170 enrolled38 locationsNCT06747585
Recruiting
Phase 2
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Unresectable Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China43 enrolled1 locationNCT07408635
Recruiting
Phase 1Phase 2
Retifanlimab and Ruxolitinib In Solid Malignancies
Renal Cell CarcinomaNon-Small-Cell Lung Carcinoma
University of California, San Diego40 enrolled1 locationNCT07219576
Recruiting
Phase 2
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
Non-small-cell Lung Cancer Patients
Fondazione Ricerca Traslazionale176 enrolled1 locationNCT05568212
Recruiting
Phase 1Phase 2
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523
Recruiting
Phase 1Phase 2
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Triple-Negative Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma+7 more
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 2
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Non-Small-Cell Lung CarcinomaEGFR Gene MutationAdvanced Non-Small Cell Squamous Lung Cancer
The Netherlands Cancer Institute16 enrolled1 locationNCT06222489